Morgan Stanley
AVBP icon

Morgan Stanley’s ArriVent BioPharma AVBP Stock Holding History

Morgan Stanley’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.97M Buy
128,546
+30,956
+32% +$699K ﹤0.01% 4477
2025
Q4 		$1.96M Sell
97,590
-294,432
-75% -$6.13M ﹤0.01% 4823
2025
Q3 		$7.23M Buy
392,022
+290,668
+287% +$5.71M ﹤0.01% 3842
2025
Q2 		$2.21M Sell
101,354
-20,584
-17% -$427K ﹤0.01% 4637
2025
Q1 		$2.25M Sell
121,938
-26,646
-18% -$652K ﹤0.01% 4524
2024
Q4 		$3.96M Sell
148,584
-19,150
-11% -$550K ﹤0.01% 4190
2024
Q3 		$3.94M Buy
167,734
+126,350
+305% +$2.87M ﹤0.01% 4143
2024
Q2 		$768K Buy
41,384
+20,243
+96% +$361K ﹤0.01% 5111
2024
Q1 		$378K Buy
+21,141
New +$426K ﹤0.01% 5434

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley's AVBP Position: Q1 2026 in Review

Morgan Stanley increased its ArriVent BioPharma (AVBP) stake by 32% in Q1 2026, buying an estimated $699K and bringing the position to 128,546 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #4477.

Morgan Stanley first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $7.23M in Q3 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Morgan Stanley held 128,546 shares of ArriVent BioPharma worth $2.97M as of Q1 2026.
  • Morgan Stanley bought 30,956 ArriVent BioPharma shares in Q1 2026, an estimated $699K.
  • ArriVent BioPharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4477 holding.
  • Morgan Stanley first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Morgan Stanley's ArriVent BioPharma position peaked at $7.23M in Q3 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.